Ra Capital Management, L.P. Relmada Therapeutics, Inc. Transaction History

Ra Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $33.9 Million - $53.6 Million	2,000,000 New	2,000,000 $45.1 Million
Q4 2020 Feb 16, 2021	SELL	$29.88 - $39.8 $23.3 Million - $31.1 Million	-781,290 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$34.42 - $43.78 $2.43 Million - $3.09 Million	-70,617 Reduced 8.29%	781,290 $29.4 Million
Q2 2020 Aug 14, 2020	SELL	$31.59 - $49.98 $16.7 Million - $26.4 Million	-528,081 Reduced 38.27%	851,907 $38.1 Million
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $14.7 Million - $31 Million	618,322 Added 81.18%	1,379,988 $47.1 Million
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $7.69 Million - $35.9 Million	761,666 New	761,666 $29.7 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $77.8M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.